Vardenafil is under clinical development by LTR Pharma and currently in Phase I for Erectile Dysfunction. According to GlobalData, Phase I drugs for Erectile Dysfunction have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Vardenafil’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vardenafil overview

Vardenafil (SDS-089) is under development for the treatment of erectile dysfunction. It is administered through intranasal route in the form of spray. It acts by targeting phosphodiesterase 5 (PDE5).

LTR Pharma overview

LTR Pharma is a biopharmaceutical company engaged in developing drugs for erectile dysfunction. It focuses on spontan intranasal spray treatment to treat erectile dysfunction. The company is headquartered in Brisbane, Queensland, Australia.

For a complete picture of Vardenafil’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.